Microcap Ledger Biovie Inc. $BIVI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Carson City, NV
- Fiscal year end
- June 30
- Shares outstanding
- 7,542,638 [10-K 2026-08-13]
What the company doesAI summary of filing
BioVie Inc. is a clinical-stage biopharmaceutical company developing drug therapies for neurological, neurodegenerative, and liver diseases. The company's primary investigational candidate is bezisterim (NE3107), an oral small molecule being evaluated in clinical trials for Parkinson's disease, Alzheimer's disease, and Long COVID, with a Phase 2b Parkinson's trial completed in August 2026 and a Phase 2 Long COVID trial that completed enrollment in May 2026. The company also develops BIV201, a continuous infusion formulation of terlipressin for treating ascites related to liver cirrhosis, which has received FDA Fast Track status and Orphan Drug designation; BIV201 is currently in Phase 2 development with Phase 3 protocol finalization underway. BioVie is pre-revenue and relies on clinical trial data and regulatory guidance to advance its candidates toward potential FDA approval. [10-K 2026-08-13]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| FY ended Jun 2026 | — | −$22.07M | −$19.02M | $8.98M | [10-K 2026-08-13] |
| FY ended Jun 2025 | — | −$17.54M | −$19.03M | $17.54M | [10-K 2026-08-13] |
- Quarterly cash burn
- −$4.76M
- Cash runway Estimate
- ~5.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 17,768,174 | [10-Q 2024-11-13] |
| 2025-02-07 | 18,451,981 | [10-Q 2025-02-11] |
| 2025-05-05 | 18,562,376 | [10-Q 2025-05-12] |
| 2025-08-15 | 7,534,225 | [10-K 2025-08-15] |
| 2025-11-07 | 7,540,316 | [10-Q 2025-11-10] |
| 2026-02-05 | 7,543,571 | [10-Q 2026-02-06] |
| 2026-05-11 | 7,541,839 | [10-Q 2026-05-11] |
| 2026-08-10 | 7,542,638 | [10-K 2026-08-13] |
- Shelf registration
- S-1 filed 2026-07-17; no effectiveness notice found in EDGAR [S-1 2026-07-17]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-28 | Palumbo Joseph M | buy | 4,843 | $2.16 | [4 2026-08-28] |
| 2026-08-28 | Chappell Amy Suzon | buy | 727 | $2.16 | [4 2026-08-28] |
| 2026-08-28 | Kim Joanne Wendy | buy | 2,500 | $2.18 | [4 2026-08-28] |
| 2026-08-27 | Do Cuong V | buy | 15,210 | $2.08 | [4 2026-08-28] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | DEF 14A | Proxy statement |
| 2026-09-14 | 8-K | Material agreement entered |
| 2026-09-14 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-03 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-19 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | S-1/A | Registration statement |
| 2026-08-13 | 10-K | Annual report |
| 2026-08-07 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | S-1/A | Registration statement |
| 2026-08-06 | 8-K | Regulation FD disclosure |
| 2026-07-31 | S-1/A | Registration statement |
Alerts for $BIVI
Email me when Biovie Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.